Stockreport

Coya Therapeutics Presents Updated ALS Biomarker Data at the 2nd Annual Johnson Center Symposium [Yahoo! Finance]

Coya Therapeutics, Inc.  (COYA) 
PDF Serum 4-HNE levels are increased in bulbar vs. limb onset ALS patients and correlate with shortened survival in patients with bulbar onset ALS; Serum 4-HNE Receiver O [Read more]